Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Q1 2026 · 10-Q
Revenue$0.00$0.00— vs Q1 2025 Net Income-$15.72M-$15.72MN/M vs Q1 2025 EPS Diluted-$0.35-$0.35N/M vs Q1 2025 Operating Income-$16,573,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 12, 2026 · 42 d after period end